The Cost-Effectiveness of Preventing Cytomegalovirus Disease in AIDS Patients

A. David Paltiel and Kenneth A. Freedberg
Additional contact information
A. David Paltiel: Yale School of Medicine, 60 College Street, New Haven, Connecticut 06520-8034
Kenneth A. Freedberg: Clinical Economics Research Unit, Section of General Internal Medicine, Department of Medicine and Thorndike Memorial Laboratory, Boston Medical Center, Boston University School of Medicine, 91 East Concord Street, Suite 200, Boston, Massachusetts 02118

Interfaces, 1998, vol. 28, issue 3, 34-51

Abstract: To examine the costs and consequences of prophylaxis against cytomegalovirus (CMV) infection, we developed a compartmental model of the natural history of late-stage HIV disease. We used data on the progression of illness, economic costs, the incidence of infections, the efficacy and toxicity of therapy, and patient quality of life from national cohort studies, randomized clinical trials, and resource-utilization surveys. We found that CMV prophylaxis confers additional quality-adjusted life-years at a lower-bound, marginal cost of $160,000. While this cost-effectiveness result compares unfavorably with alternative uses of scarce resources, it is sensitive to assumptions regarding the price of therapy and the incidence of infection.

Keywords: health care; cost analysis (search for similar items in EconPapers)
Date: 1998
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://dx.doi.org/10.1287/inte.28.3.34 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:orinte:v:28:y:1998:i:3:p:34-51

Access Statistics for this article

More articles in Interfaces from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher ().